In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D ...

The healthcare company's pivot into a new set of technologies will have many implications for the stock.

Novo Nordisk CEO explains decision to discontinue the long-acting insulin Levemir. He blamed pharmacy managers and health ...

CEO Lars Fruergaard Jørgensen agreed today, during a Senate committee hearing, to sit down with lawmakers and pharmacy ...

(Reuters) -German drug and development company Evotec has entered into a technology development partnership with Novo Nordisk ...

A committee report found the weight loss drug is offered for less than $100 in some European countries, compared to monthly ...

Novo Nordisk CEO grilled over company's pricing for the diabetes drug Ozempic and the weight-loss drug Wegovy.

Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for ...

German drug and development company Evotec has entered into a technology development partnership with Novo Nordisk to support ...

2024年3月15日，尽管Novo Nordisk（NYSE:NVO）的II期肥胖试验结果不尽如人意，TD Cowen仍维持其买入评级和155.00美元的目标价。该试验研究了公司的CB1阻断剂monlunabant，在16周时显示约6-7%的体重减轻。 这次更新未能达到预期的疗效和安全性，但未发现严重的神经精神不良事件。然而，接受monlunabant治疗的参与者出现轻度至中度神经精神副作用的情况 ...

Novo Nordisk CEO Lars Fruergaard Jørgensen is testifying before the Senate Health, Education, Labor and Pension committee on ...

Novo Nordisk's chief executive is preparing for a showdown next week with U.S. Senator Bernie Sanders over the high price of ...